Virtu Financial LLC Has $1.07 Million Stake in BioNTech SE Sponsored ADR $BNTX

Virtu Financial LLC increased its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 163.9% during the fourth quarter, HoldingsChannel reports. The fund owned 11,244 shares of the company’s stock after buying an additional 6,984 shares during the quarter. Virtu Financial LLC’s holdings in BioNTech were worth $1,070,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of BNTX. Larson Financial Group LLC raised its position in BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares during the last quarter. EFG International AG acquired a new position in shares of BioNTech in the fourth quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd increased its stake in shares of BioNTech by 520.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after buying an additional 260 shares during the period. Huntington National Bank raised its holdings in BioNTech by 1,266.7% in the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after buying an additional 380 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in BioNTech by 118.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after buying an additional 305 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Morgan Stanley lifted their target price on shares of BioNTech from $125.00 to $126.00 and gave the stock an “overweight” rating in a research report on Friday, April 10th. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research note on Monday, June 1st. UBS Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the company from $117.00 to $135.00 in a research note on Wednesday, May 27th. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Finally, Raymond James Financial reissued an “outperform” rating on shares of BioNTech in a research note on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $129.56.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $90.89 on Monday. The company has a market capitalization of $22.98 billion, a P/E ratio of -15.46 and a beta of 1.33. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.74 and a current ratio of 8.80. The company’s 50 day moving average price is $94.55 and its 200-day moving average price is $98.13.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. The firm had revenue of $1.06 billion during the quarter. Equities analysts forecast that BioNTech SE Sponsored ADR will post -5.67 earnings per share for the current year.

BioNTech declared that its board has authorized a stock buyback program on Thursday, May 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to purchase up to 4.2% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.

Insider Transactions at BioNTech

In related news, COO Sierk Poetting sold 50,000 shares of the business’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the transaction, the chief operating officer owned 399,387 shares in the company, valued at $44,156,226.72. The trade was a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by insiders.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.